published meta-analysis   sensitivity analysis   studies

lopinavir/ritonavir in COVID-19 mild to moderate - Summary of results

OutcomeTE95% CInkI2ROBPub. bias clinical deteriorationdetailed resultsELACOI (lopinavir/ritonavir), 2020 3.69 [0.37; 36.57] 3.69[0.37; 36.57]ELACOI (lopinavir/ritonavir), 202010%28NAnot evaluable radiologic improvement (14-day)detailed resultsELACOI (lopinavir/ritonavir), 2020 0.48 [0.02; 11.28] 0.48[0.02; 11.28]ELACOI (lopinavir/ritonavir), 202010%25NAnot evaluable radiologic improvement (7-day)detailed resultsELACOI (lopinavir/ritonavir), 2020 0.10 [0.00; 2.09] 0.10[0.00; 2.09]ELACOI (lopinavir/ritonavir), 202010%25NAnot evaluable viral clearance detailed resultsELACOI (lopinavir/ritonavir), 2020 1.28 [0.19; 8.76] 1.28[0.19; 8.76]ELACOI (lopinavir/ritonavir), 202010%28NAnot evaluable viral clearance by day 14detailed resultsELACOI (lopinavir/ritonavir), 2020 1.28 [0.19; 8.76] 1.28[0.19; 8.76]ELACOI (lopinavir/ritonavir), 202010%28NAnot evaluable viral clearance by day 7detailed resultsELACOI (lopinavir/ritonavir), 2020 0.30 [0.05; 1.91] 0.30[0.05; 1.91]ELACOI (lopinavir/ritonavir), 202010%28NAnot evaluable0.05.01.0relative treatment effectwww.metaEvidence.org2024-11-01 00:12 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 90 - treatments: 509 - roots T: 290